Key result
B-type natriuretic peptide (BNP) testing correlates with ventricular function and prognosis, offering strong negative predictive value for diagnosing congestive heart failure in acute dyspnea.
Answers are grounded in this paper and cite their sources.
BNP is a valuable biomarker for diagnosing heart failure, assessing prognosis, and potentially guiding management and screening high-risk patients.
Congestive heart failure poses significant challenges to physicians with both diagnosis and management. B-type natriuretic peptide (BNP) is synthesized in the cardiac ventricles. It correlates with ventricular function, NYHA classification, and prognosis. It is extremely useful in the emergency department in patients presenting with acute dyspnea. It has a particularly strong negative predictive value. In addition, it should be important in screening patients for heart diease, either for those who are at high risk (chemotherapy, diabetes) or as a possible screen before echocardiography. In the future, BNP may be used to modulate treatment of patients in the decompensated setting as well as in titrating outpatient therapy.
No takes yet. Share an insight, caveat, or question.
Tabbibizar et al. (2002) conducted a review in Congestive heart failure. B-type natriuretic peptide (BNP) testing was evaluated. B-type natriuretic peptide (BNP) testing correlates with ventricular function and prognosis, offering strong negative predictive value for diagnosing congestive heart failure in acute dyspnea.
Synapse has enriched 10 related papers. Consider them for comparative context: